Ardsley Advisory Partners bought a new stake in shares of Catalyst Biosciences Inc (NASDAQ:CBIO) in the 4th quarter, Holdings Channel reports. The fund bought 15,000 shares of the biopharmaceutical company’s stock, valued at approximately $205,000.
Several other large investors have also recently bought and sold shares of CBIO. Vanguard Group Inc. increased its holdings in shares of Catalyst Biosciences by 294.1% during the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 32,621 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Catalyst Biosciences during the 2nd quarter valued at approximately $372,000. Geode Capital Management LLC purchased a new position in shares of Catalyst Biosciences during the 4th quarter valued at approximately $379,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Catalyst Biosciences by 6.5% during the 4th quarter. Renaissance Technologies LLC now owns 355,373 shares of the biopharmaceutical company’s stock valued at $4,847,000 after purchasing an additional 21,600 shares in the last quarter. 26.48% of the stock is owned by hedge funds and other institutional investors.
In related news, insider James E. Flynn sold 71,778 shares of Catalyst Biosciences stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $30.53, for a total value of $2,191,382.34. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder James E. Flynn sold 52,461 shares of Catalyst Biosciences stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $30.87, for a total transaction of $1,619,471.07. The disclosure for this sale can be found here. 5.00% of the stock is currently owned by company insiders.
Shares of Catalyst Biosciences Inc (CBIO) opened at $27.14 on Wednesday. Catalyst Biosciences Inc has a one year low of $3.11 and a one year high of $37.00. The stock has a market cap of $307.45, a price-to-earnings ratio of -2.89 and a beta of 2.58.
Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.41) by $0.45. Catalyst Biosciences had a negative net margin of 2,117.98% and a negative return on equity of 93.68%. The firm had revenue of $0.32 million for the quarter, compared to analysts’ expectations of $0.23 million. research analysts anticipate that Catalyst Biosciences Inc will post -4.16 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.themarketsdaily.com/2018/03/14/ardsley-advisory-partners-takes-205000-position-in-catalyst-biosciences-inc-cbio.html.
Catalyst Biosciences Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Want to see what other hedge funds are holding CBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Biosciences Inc (NASDAQ:CBIO).
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.